Thus, we expected the Bi-FAP/mEnd-IL to simultaneously target the tumor cells (based on human FAP), TAFs (based on murine FAP of host mouse) [5], tumor vasculature (based on murine endoglin) [32] and TAMs (based on phagocytic uptake) [33]. The gene discussed is FAP; the disease is neoplasm.